Meclizine hydrochloride tablets, USP Rx Only

Manufacturer
DOH CENTRAL PHARMACY
Effective date
2019-01-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:27:34

Label at a glance#

ProductMECLIZINE HYDROCHLORIDE
Active ingredientMECLIZINE HYDROCHLORIDE
Label structure10 sections

Indications and uses

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system.

Dosage and administration

For the treatment of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100 mg daily, in divided dosage, depending upon clinical response.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Chemically, Meclizine HCl is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.

Structure of Meclizine HClStructure of Meclizine HCl

     C25H27ClN2 • 2HCl•H2O                                        Molecular Weight 481.88

Meclizine hydrochloride tablets, USP are available in two different strengths: 12.5 mg and 25 mg. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose. Also, Meclizine hydrochloride tablets USP, 12.5 mg contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine hydrochloride tablets USP, 25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Meclizine hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

PHARMACOKINETICS SECTION

Pharmacokinetics
The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.

SPL UNCLASSIFIED SECTION

Absorption
Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median Tmax value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

SPL UNCLASSIFIED SECTION

Distribution
Drug distribution characteristics for meclizine in humans are unknown.

SPL UNCLASSIFIED SECTION

Metabolism
The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultra-rapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.

SPL UNCLASSIFIED SECTION

Elimination
Meclizine has a plasma elimination half-life of about 5-6 hours in humans.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Meclizine hydrochloride tablets are contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

WARNINGS SECTION

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

PRECAUTIONS

PRECAUTIONS SECTION

SPL UNCLASSIFIED SECTION

Pediatric Use
Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

SPL UNCLASSIFIED SECTION

Pregnancy
Pregnancy Category B.
Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

SPL UNCLASSIFIED SECTION

Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.

SPL UNCLASSIFIED SECTION

Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.

SPL UNCLASSIFIED SECTION

Renal Impairment
The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential for drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.

SPL UNCLASSIFIED SECTION

Drug Interactions
There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives. (see WARNINGS).

Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Jubilant Cadista Pharmaceuticals Inc. at 1-800-313-4623 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For the treatment of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100 mg daily, in divided dosage, depending upon clinical response.

HOW SUPPLIED

HOW SUPPLIED SECTION

Meclizine hydrochloride tablets, USP are available in the following strengths:

12.5 mg (Blue, oval shaped tablets, debossed with “TL 122” with score on one side and plain on the other side.)

25 mg (Yellow, oval shaped tablets, debossed with “TL 121” with score on one side and plain on the other side.)

They are supplied by DOH CENTRAL PHARMACY as follows:

NDCStrengthQuantity/FormColorSource Prod. Code
53808-1116-125 MG30 Tablets in a Blister PackYELLOW59746-121

Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].

Manufactured By:
Jubilant Cadista Pharmaceuticals Inc.
Salisbury, MD 21801, USA

This Product was Repackaged By:

DOH CENTRAL PHARMACY
104 HAMILTON PARK DR # 2
TALLAHASSEE, FL 32304
USA

PACKAGE LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image for 53808-1116
25mg

Label Image for 25mg
Label Image for 25mg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
995666meclizine HCl 25 MG Oral TabletPSN1
995666meclizine hydrochloride 25 MG Oral TabletSCD1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
MECLIZINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
ac6963c4-31c6-325f-ee58-83a0a06597adProduct name520221206

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
53808-1116-12024-01-30C16284748780-11030e365-6694-111a-e063-dadaa90a10e2Meclizine hydrochloride tablets, USP Rx Only

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
53808-1116-1MECLIZINE HYDROCHLORIDE30 in 1 BLISTER PACKTABLET301

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
53808-1116MECLIZINE HYDROCHLORIDE (MECLIZINE HYDROCLORIDE) TABLET [DOH CENTRAL PHARMACY]1Legacy NDC, 1 package rows20190122_478bac81-1b81-4c8e-b894-019c5a039b6d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
59746-121-06EA - Each59746-121426b1544-2026-4b5e-92b6-b06bf4ad888312012-07-24
59746-121-10EA - Each59746-121ef373495-c09a-4243-9246-5944249609e512012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
53808-111653808-1116-1
59746-121

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040659-001MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04
A040659-002MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A040659-001AA
A040659-002AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-0484e616aacf4f…
2026-09-14 22:38:342026-08A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-0484e616aacf4f…
2026-08-18 06:07:402026-07A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04caaa826d4ba7…
2026-08-18 06:07:402026-07A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-0431067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-0431067a03dcf5…
2025-08-23 18:47 UTC2025-08A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-046a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-046a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-0403ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-0403ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-042680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-042680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-045bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-045bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04d06236e962d9…
2024-10-29 15:01 UTC2024-10A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-0479d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-0479d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-04301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-04301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-041e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-041e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-048072bd15b7f6…
2024-05-31 18:47 UTC2024-05A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-048072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-045c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-045c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-045d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-045d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-044b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-044b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040659-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2010-06-0474a2ff9319b5…
2019-12-13 00:20 UTC2019-12A040659-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2010-06-0474a2ff9319b5…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A040659-001AA184e616aacf4f…
2026-09-14 22:38:342026-08A040659-002AA184e616aacf4f…
2026-08-18 06:07:402026-07A040659-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A040659-002AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040659-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A040659-002AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040659-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040659-002AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040659-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A040659-002AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040659-001AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040659-002AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040659-001AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040659-002AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040659-001AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040659-002AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040659-001AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040659-002AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040659-001AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040659-002AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040659-001AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040659-002AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040659-001AA1d06236e962d9…
2024-10-29 15:01 UTC2024-10A040659-002AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040659-001AA179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040659-002AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040659-001AA1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040659-002AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040659-001AA11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040659-002AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040659-001AA18072bd15b7f6…
2024-05-31 18:47 UTC2024-05A040659-002AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040659-001AA15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040659-002AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040659-001AA15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A040659-002AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040659-001AA14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A040659-002AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040659-001AA174a2ff9319b5…
2019-12-13 00:20 UTC2019-12A040659-002AA174a2ff9319b5…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCLORIDEJubilant Cadista Pharmacuticals Inc.9350fefc-9c00-182c-c3a9-044d4a40856f2025-07-31Warnings, Adverse reactionsExact identifier
ndc (product): 59746-121
a804d650-9d29-447a-b311-87f1e4b43cab478bac81-1b81-4c8e-b894-019c5a039b6d2019-01-18Warnings, Adverse reactionsExact identifier
spl id: a804d650-9d29-447a-b311-87f1e4b43cab
spl set id: 478bac81-1b81-4c8e-b894-019c5a039b6d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.